Biocryst Drug Patent Portfolio

Biocryst owns 2 orange book drugs protected by 12 US patents Given below is the list of Biocryst's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10662160 Crystalline salts of a plasma kallikrein inhibitor 01 Nov, 2039
Active
US11117867 Crystalline salts of a plasma kallikrein inhibitor 01 Nov, 2039
Active
US11618733 Crystalline salts of a plasma kallikrein inhibitor 01 Nov, 2039
Active
US10125102 Human plasma kallikrein inhibitors 07 Apr, 2035
Active
US10329260 Human plasma kallikrein inhibitors 09 Mar, 2035
Active
US10689346 Human plasma kallikrein inhibitors 09 Mar, 2035
Active
US11230530 Human plasma kallikrein inhibitors 09 Mar, 2035
Active
US11708333 Human plasma kallikrein inhibitors 09 Mar, 2035
Active
US8778997 Antiviral treatments 07 May, 2027
Active
US10391075 Antiviral treatments 12 Feb, 2027
Active
US6562861 Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors 16 Dec, 2023 Expired
US6503745 Cyclopentane and cyclopentene compounds and use for detecting influenza virus 05 Nov, 2019 Expired


Given below is the list of recent legal activities going on the following drug patents of Biocryst.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 28 Nov, 2023 US10689346
Payment of Maintenance Fee, 4th Year, Large Entity 16 Nov, 2023 US10662160
Patent eGrant Notification 25 Jul, 2023 US11708333
Patent Issue Date Used in PTA Calculation 25 Jul, 2023 US11708333
Mail Patent eGrant Notification 25 Jul, 2023 US11708333
Email Notification 25 Jul, 2023 US11708333
Recordation of Patent eGrant 25 Jul, 2023 US11708333
Recordation of Patent Grant Mailed 25 Jul, 2023 US11708333
Electronic Review 25 Jul, 2023 US11708333
Email Notification 06 Jul, 2023 US11708333
Electronic Review 06 Jul, 2023 US11708333
Issue Notification Mailed 05 Jul, 2023 US11708333
Dispatch to FDC 09 Jun, 2023 US11708333
Application Is Considered Ready for Issue 09 Jun, 2023 US11708333
Issue Fee Payment Verified 18 Apr, 2023 US11708333


Biocryst's Family Patents

Biocryst drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 23.3% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Biocryst Drug List

Given below is the complete list of Biocryst's drugs and the patents protecting them.


1. Orladeyo

Orladeyo is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10662160 Crystalline salts of a plasma kallikrein inhibitor 01 Nov, 2039
(15 years from now)
Active
US11117867 Crystalline salts of a plasma kallikrein inhibitor 01 Nov, 2039
(15 years from now)
Active
US11618733 Crystalline salts of a plasma kallikrein inhibitor 01 Nov, 2039
(15 years from now)
Active
US10125102 Human plasma kallikrein inhibitors 07 Apr, 2035
(10 years from now)
Active
US10329260 Human plasma kallikrein inhibitors 09 Mar, 2035
(10 years from now)
Active
US10689346 Human plasma kallikrein inhibitors 09 Mar, 2035
(10 years from now)
Active
US11230530 Human plasma kallikrein inhibitors 09 Mar, 2035
(10 years from now)
Active
US11708333 Human plasma kallikrein inhibitors 09 Mar, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orladeyo's drug page


2. Rapivab

Rapivab is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8778997 Antiviral treatments 07 May, 2027
(2 years from now)
Active
US10391075 Antiviral treatments 12 Feb, 2027
(2 years from now)
Active
US6562861 Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors 16 Dec, 2023
(9 months ago)
Expired
US6503745 Cyclopentane and cyclopentene compounds and use for detecting influenza virus 05 Nov, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapivab's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List